Table 3 Comparison of subjects with and without colistin-resistant E. coli or K. pneumoniae colonization at study enrollment
Variables | Colonization at enrollment (n = 24) | No colonization at enrollment (n = 115) | p-value |
|---|---|---|---|
Female gender | 13 (54.2%) | 57 (49.6%) | 0.68 |
Age (yrs), mean ± SD | 64.3 ± 18.8 | 67.8 ± 15.2 | 0.33 |
ICU admission, n (%) | 9 (37.5%) | 39 (33.9%) | 0.77 |
Previous hospitalization, n (%) | 15 (62.5%) | 58 (50.4%) | 0.28 |
Duration from hospital admission to enrollment (days), median (range) | 19.5 (4–106) | 15 (1–86) | 0.10 |
Duration from enrollment to first sample collection (days), median (range) | 1.5 (1–4) | 1 (1–5) | 0.48 |
APACHE II score at study enrollment, mean ± SD | 20.6 ± 7.2 | 21.9 ± 7.4 | 0.65 |
Mechanical ventilation, n (%) | 20 (83.3%) | 97 (84.3%) | 1.0 |
Indwelling central venous catheter, n (%) | 17 (70.8%) | 68 (59.1%) | 0.29 |
Surgery, n (%) | 19 (79.2%) | 65 (56.5%) | 0.04 |
Chronic intermittent hemodialysis, n (%) | 4 (16.7%) | 14 (12.2%) | 0.74 |
Colistin use within 3Â months prior to study enrollment, n (%) | 4 (16.7%) | 11 (9.6%) | 0.47 |
Antibiotic use for the current hospitalization prior to study enrollment, n (%) | |||
 Carbapenems | 20 (83.3%) | 92 (80.0%) | 0.79 |
 Cephalosporins | 9 (37.5%) | 47 (40.9%) | 0.76 |
 Beta-lactam/beta-lactamase inhibitors | 16 (66.7%) | 59 (51.3%) | 0.17 |
 Fluoroquinolones | 13 (54.2%) | 26 (22.6%) | 0.002 |
 Vancomycin | 13 (54.2%) | 30 (26.1%) | 0.007 |
 Aminoglycosides | 3 (12.5%) | 3 (2.6%) | 0.06 |
 Colistin | 3 (13.6%) | 6 (5.5%) | 0.36 |
Length of hospital stay (days), median (range) | 49.5 (13–138) | 36 (6–246) | 0.17 |
All-cause mortality at hospital discharge, n (%) | 16 (66.7%) | 54 (47.0%) | 0.08 |